RxDoctor Payments Data

Keya Malhotra

Geriatric Medicine · Lubbock, TXNPI 1083927271

Payments from drug & device makers

$981in general payments, 2019–2025

Across 40 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$222
  • Astellas Pharma US Inc$199
  • Axsome Therapeutics, Inc.$108
  • Eisai Inc.$99
  • Takeda Pharmaceuticals U.S.A., Inc.$88
  • Lilly USA, LLC$76
  • plus $190 from 6 others

What the payments were for

  • Food & beverage$88690%
  • Education$9510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$981 in reported general payments places this provider in the 75th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$270,877
Medicare patients
482
Services billed
4,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron194$157,808
EliquisApixaban134$141,150
MounjaroTirzepatide127$138,024
JanuviaSitagliptin Phosphate127$134,839
OzempicSemaglutide110$103,579
FarxigaDapagliflozin Propanediol80$85,938
LinzessLinaclotide43$40,761
JardianceEmpagliflozin35$31,749
Mirabegron ErMirabegron37$22,427
TrintellixVortioxetine Hydrobromide21$19,498
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$14,547
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$13,097
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$12,468
GemtesaVibegron25$12,189
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$12,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$199$157,808194 claims
PfizerEliquis$32$141,150134 claims
Lilly USA, LLCMounjaro$76$138,024127 claims
Novo NordiskOzempic$11$103,579110 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$88$19,49821 claims
Sumitomo Pharma America, Inc.Gemtesa$222$12,18925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →